成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Immunology/Inflammation
  3. CD20
  4. Obinutuzumab

Obinutuzumab  (Synonyms: 奧濱尤妥珠單抗; GA101; Anti-Human CD20 type II, Humanized Antibody)

目錄號: HY-P9910 純度: ≥99.4%
COA 技術(shù)支持

Obinutuzumab (GA101) 是新型糖工程化 II 型 CD20 人源化 IgG1 單克隆抗體，用于非霍奇金淋巴瘤的研究。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

我們將采用定制合成服務(wù)的方式為您快速提供所需產(chǎn)品和技術(shù)服務(wù)

CAS No. : 949142-50-1

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
1 mg ￥2450
In-stock
5 mg ￥7313
In-stock
10 mg   詢價(jià)  
50 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 實(shí)驗(yàn)參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.

同型

Human IgG1 kappa
推薦同型對照抗體
種屬

Humanized
體外研究
(In Vitro)

Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
體內(nèi)研究
(In Vivo)

Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed[2]. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab[1]. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
CAS 號
性狀

液體

顏色

Colorless to light yellow

中文名稱

奧濱尤妥珠單抗；阿托珠單抗； 奧拓珠單抗
儲存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Obinutuzumab has a significant ADCC effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 0.46 ng/mL.
純度 & 產(chǎn)品資料

純度: ≥99.4%

參考文獻(xiàn)
Animal Administration
[2]

Mice: For xenograft experiments, 1×106 RL cells are injected subcutaneously on day 1. Mice are randomized when a tumor becomes palpable in groups of 10 and treatment is initiated. In a first set of experiments, rituximab and obinutuzumab are used as monotherapy at different dosages twice weekly. The 5 different groups of 10 mice are: control group receiving vehicle (NaCl 0.9%), rituximab (30 mg/kg), obinutuzumab (10 mg/kg), obinutuzumab (30 mg/kg), and obinutuzumab (100 mg/kg). The treatment is administered intravenously twice a week. The mice are closely monitored regarding weight and general status[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量   濃度   體積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start) × 體積 (start) = 濃度 (final) × 體積 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Obinutuzumab
目錄號：
HY-P9910
需求量：